Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents

被引：0
|
作者：
Finn, R. S.
Lau, A.
Kalous, O.
Conklin, D.
Dering, J.
Knights, C.
O'Shaughnessy, A.
Cranston, A.
Riches, L.
Carmichael, J.
O'Connor, M. J.
Slamon, D. J.
机构：
[1] KuDOS Pharmaceut, Cambridge, England
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117S / 117S
页数：1
相关论文
共 50 条
  • [41] Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
    Sushmita B. Gordhandas
    Beryl Manning-Geist
    Christina Henson
    Gopa Iyer
    Ginger J. Gardner
    Yukio Sonoda
    Kathleen N. Moore
    Carol Aghajanian
    M. Herman Chui
    Rachel N. Grisham
    Scientific Reports, 12
  • [42] The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(-) triple-negative breast cancer (TNBC) cell line
    Ossovskaya, Valeria
    Lim, Chang-Uk
    Schools, Gary
    Kalurupalle, Swathi
    Roninson, Igor B.
    Broude, Eugenia
    CANCER RESEARCH, 2011, 71
  • [43] A COMBINATION OF 2 IMMUNOTOXINS EXERTS SYNERGISTIC CYTOTOXIC ACTIVITY AGAINST HUMAN BREAST-CANCER CELL-LINES
    CREWS, JR
    MAIER, LA
    YIN, HY
    HESTER, S
    OBRIANT, K
    LESLIE, DS
    DESOMBRE, K
    GEORGE, SL
    BOYER, CM
    ARGON, Y
    BAST, RC
    INTERNATIONAL JOURNAL OF CANCER, 1992, 51 (05) : 772 - 779
  • [44] Aberrant DNA methyltransferase 3b activity accounts for the hypermethylator phenotype in human breast cancer cell lines
    Risher, J. Devon
    Coleman, William B.
    FASEB JOURNAL, 2007, 21 (06): : A755 - A756
  • [45] Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin
    Kozar, K
    Kaminski, R
    Legat, M
    Kopec, M
    Nowis, D
    Skierski, JS
    Koronkiewicz, M
    Jakóbisiak, M
    Golab, J
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 24 (05) : 1149 - 1157
  • [46] Enhanced antitumor activity of TLK286 in combination with carboplatin, doxorubicin and docetaxel in human ovarian and breast cancer cell lines
    Keck, J
    Meng, F
    Grossman, E
    Cai, D
    Brown, G
    Schow, S
    Xu, H
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S35 - S35
  • [47] Biologic Activity of a Novel Heat Shock Protein 90 Inhibitor, PF-4928473, in Human Breast Cancer Cell Lines
    Tsang, R. Y.
    Conklin, D.
    Kalous, O.
    Desai, A.
    Dering, J.
    Ginther, C.
    Christensen, J.
    Slamon, D. J.
    Finn, R. S.
    CANCER RESEARCH, 2010, 70
  • [48] SNS-314, a selective Aurora kinase inhibitor with potent, pre-clinical antitumour activity, shows broad therapeutic potential in combination with standard chemotherapeutics and synergy with microtubule targeted agents
    Chan, E.
    Fucini, R.
    Zimmerman, K.
    Bui, M.
    Hogan, J.
    Jackson, M.
    Taverna, P.
    Howlett, A.
    Flanagan, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 90 - 90
  • [49] Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines
    Wigington, DP
    Urben, CM
    Strugnell, SA
    Knutson, JC
    ANTICANCER RESEARCH, 2004, 24 (5A) : 2905 - 2912
  • [50] Ipatasertib (GDC-0068), a novel Akt inhibitor, synergizes with anti-microtubule chemotherapic agents in human breast cancer cell lines
    Della Corte, C. M.
    Orditura, M.
    Diana, A.
    Di Mauro, C.
    Ciaramella, V.
    De Vita, F.
    Ciardiello, F.
    Morgillo, F.
    ANNALS OF ONCOLOGY, 2016, 27
12345